Literature DB >> 21570848

Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs.

Deborah M Fine1, Jin-Hong Shin, Yongping Yue, Dietrich Volkmann, Stacey B Leach, Bruce F Smith, Mark McIntosh, Dongsheng Duan.   

Abstract

The absence of dystrophin in the heart leads to Duchenne cardiomyopathy. Dystrophin-deficient dogs represent a critical model to translate novel therapies developed in mice to humans. Unfortunately, little is known about cardiophysiology changes in these dogs. We performed prospective electrocardiographic and echocardiographic examinations at 3, 6 and 12 months of age in four normal and three affected dogs obtained from the same litter. Affected dogs showed growth retardation and serum creatine kinase elevation. Necropsy confirmed cardiac dystrophin deficiency and histopathology. Q/R ratio elevation and diastolic left ventricular (LV) internal diameter reduction were the most consistent findings in affected dogs at all ages. At 6 and 12 months, dystrophic dogs also showed significant reduction of PR intervals, LV end diastolic/systolic volumes and systolic LV internal diameters. Epicardial and endocardial slope times were significantly reduced in affected dogs at 12 months. These results establish the baseline for evaluating experimental therapies in the future.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570848      PMCID: PMC3298689          DOI: 10.1016/j.nmd.2011.03.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  61 in total

1.  Holter electrocardiogram should be systematic in Duchenne muscular dystrophy.

Authors:  A Fayssoil
Journal:  Int J Cardiol       Date:  2007-07-27       Impact factor: 4.164

2.  Duchenne muscular dystrophy: how bad is the heart?

Authors:  Elizabeth M McNally
Journal:  Heart       Date:  2008-08       Impact factor: 5.994

Review 3.  New approaches in the therapy of cardiomyopathy in muscular dystrophy.

Authors:  Elizabeth M McNally
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

Review 4.  Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy.

Authors:  Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

5.  Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71.

Authors:  Nobuyuki Urasawa; Michiko R Wada; Noboru Machida; Katsutoshi Yuasa; Yoshiki Shimatsu; Yoshito Wakao; Shigeki Yuasa; Toshiaki Sano; Ikuya Nonaka; Akinori Nakamura; Shin'ichi Takeda
Journal:  Circulation       Date:  2008-05-05       Impact factor: 29.690

6.  Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

Authors:  Brian Bostick; Yongping Yue; Yi Lai; Chun Long; Dejia Li; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

7.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

8.  Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression.

Authors:  Brian Bostick; Yongping Yue; Chun Long; Dongsheng Duan
Journal:  Circ Res       Date:  2007-10-25       Impact factor: 17.367

9.  Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.

Authors:  Zejing Wang; Christian S Kuhr; James M Allen; Michael Blankinship; Paul Gregorevic; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454

10.  An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed.

Authors:  Bruce F Smith; Yongping Yue; Philip R Woods; Joe N Kornegay; Jin-Hong Shin; Regina R Williams; Dongsheng Duan
Journal:  Lab Invest       Date:  2010-08-16       Impact factor: 5.662

View more
  32 in total

1.  High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia.

Authors:  Zoe White; Chady H Hakim; Marine Theret; N Nora Yang; Fabio Rossi; Dan Cox; Gordon A Francis; Volker Straub; Kathryn Selby; Constadina Panagiotopoulos; Dongsheng Duan; Pascal Bernatchez
Journal:  J Clin Lipidol       Date:  2020-05-29       Impact factor: 4.766

Review 2.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

3.  Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy.

Authors:  Pamela Barraza-Flores; Tatiana M Fontelonga; Ryan D Wuebbles; Hailey J Hermann; Andreia M Nunes; Joe N Kornegay; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2019-08-15       Impact factor: 6.150

4.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

Review 5.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

6.  A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Arun Srivastava; Bruce Smith; Yi Lai; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2011-12-14       Impact factor: 5.695

7.  Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Bruce Smith; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2012-01-11       Impact factor: 5.695

8.  AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart.

Authors:  Xiufang Pan; Yongping Yue; Keqing Zhang; Chady H Hakim; Kasun Kodippili; Thomas McDonald; Dongsheng Duan
Journal:  Hum Gene Ther Methods       Date:  2015-04-01       Impact factor: 2.396

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.